Intraocular Inflammation with faricimab: insights from Manufacturer and User Facility Device Experience (MAUDE) database
<p dir="ltr">Since its introduction in 2019, brolucizumab’s safety has been called into question due to numerous reports of IOI following intravitreal injections. In 2020, post-marketing data showed that there was a confirmed safety alarm of severe ocular adverse events such as retin...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p dir="ltr">Since its introduction in 2019, brolucizumab’s safety has been called into question due to numerous reports of IOI following intravitreal injections. In 2020, post-marketing data showed that there was a confirmed safety alarm of severe ocular adverse events such as retinal vasculitis, and retinal vascular occlusion that may lead to severe visual acuity loss. These events were reported at rates of 3.61 and 2.35 per 10,000 injections, respectively. New concerns have been raised by Thangamathesvaran et al. on intraocular inflammation (IOI) after intravitreal faricimab (Vabysmo). Therefore, investigating underlying risk factors for IOI development following faricimab would enhance our understanding of this safety concern and inform clinical decision-making.</p><h2>Other Information</h2><p dir="ltr">Published in: Eye<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1038/s41433-024-03079-0" target="_blank">https://dx.doi.org/10.1038/s41433-024-03079-0</a></p> |
|---|